Literature DB >> 8740254

Retinal nitro blue tetrazolium staining and catalase activity in rat models of diabetes.

H Zhang1, C D Agardh, E Agardh.   

Abstract

BACKGROUND: Recent studies have suggested that reactive oxygen species may be involved in the development of diabetic retinopathy.
METHODS: Nitro blue tetrazolium (NBT) staining, a marker of reductants which may be induced by free radicals such as superoxide, and catalase activity, as an indirect measure of hydrogen peroxide (H2O2) generation, were studied in the rat retina in three conditions known to cause diabetes-like retinopathy, i.e. rats with spontaneous diabetes (the BB Wistar rat), rats with streptozotocin-induced diabetes mellitus, and rats fed on galactose. Male Wistar BB rats were studied 4-10 weeks after diagnosis of diabetes. Streptozotocin (60 mg/kg) was injected i.p. at 8 weeks of age and the experiments were performed after 8 weeks of diabetes. Young Sprague-Dawley rats were fed a 50% galactose diet for 9, 12 or 22 months.
RESULTS: In trypsinized vessel preparations, more intense NBT staining was observed only in rats fed a galactose diet for 22 months. In cross sections, the number of stained vessels were increased in BB rats (p < 0.01), but not in rats with streptozotocin-induced diabetes. Catalase activity did not differ between any of the experimental groups and their matched controls.
CONCLUSIONS: Increased amount of NBT reductants in retinal vessels occurred in BB Wistar rats and to some extent in galactose-fed rats, indicating a possible role for free radicals in the development of diabetic retinopathy. There was no evidence of increased retinal H2O2 production or activation of catalase, indicating that this particular enzyme was not affected during the conditions studied.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740254     DOI: 10.1007/bf00220708

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  27 in total

1.  Retinal vascular patterns. VI. Mural cells of the retinal capillaries.

Authors:  T KUWABARA; D G COGAN
Journal:  Arch Ophthalmol       Date:  1963-04

2.  Studies of retinal vascular patterns. I. Normal architecture.

Authors:  T KUWABARA; D G COGAN
Journal:  Arch Ophthalmol       Date:  1960-12

Review 3.  Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease.

Authors:  G Pugliese; R G Tilton; J R Williamson
Journal:  Diabetes Metab Rev       Date:  1991-03

4.  Lipid peroxide level in plasma of diabetic patients.

Authors:  Y Sato; N Hotta; N Sakamoto; S Matsuoka; N Ohishi; K Yagi
Journal:  Biochem Med       Date:  1979-02

5.  A method for assay of catalase with the oxygen cathode.

Authors:  D B Goldstein
Journal:  Anal Biochem       Date:  1968-09       Impact factor: 3.365

Review 6.  Tetrazolium salts and formazans.

Authors:  F P Altman
Journal:  Prog Histochem Cytochem       Date:  1976

7.  Lipid peroxidation and retinopathy in streptozotocin-induced diabetes.

Authors:  D Armstrong; F al-Awadi
Journal:  Free Radic Biol Med       Date:  1991       Impact factor: 7.376

8.  Superoxide dismutase activity in diabetic rat retina.

Authors:  T Nishida; S Nakagawa; R Manabe
Journal:  Jpn J Ophthalmol       Date:  1984       Impact factor: 2.447

9.  Degenerated intramural pericytes ('ghost cells') in the retinal capillaries of diabetic rats.

Authors:  W G Robison; M L McCaleb; L G Feld; O E Michaelis; N Laver; M Mercandetti; W G Robinson
Journal:  Curr Eye Res       Date:  1991-04       Impact factor: 2.424

10.  Increased catalase levels and hypoxanthine-enhanced nitro-blue tetrazolium staining in rat retina after ischemia followed by recirculation.

Authors:  H Zhang; C D Agardh; E Agardh
Journal:  Curr Eye Res       Date:  1995-01       Impact factor: 2.424

View more
  1 in total

1.  Catalase therapy corrects oxidative stress-induced pathophysiology in incipient diabetic retinopathy.

Authors:  Courtney R Giordano; Robin Roberts; Kendra A Krentz; David Bissig; Deepa Talreja; Ashok Kumar; Stanley R Terlecky; Bruce A Berkowitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-05       Impact factor: 4.799

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.